SEHK:2142Biotechs
HBM Holdings (SEHK:2142) Valuation Check After Positive LET003 Obesity Antibody Preclinical Data
HBM Holdings (SEHK:2142) is in focus after Harbour BioMed reported preclinical data for LET003, an ACVR2A/2B-targeting antibody developed using its AI-based Hu-mAtrIx platform, showing superior pharmacokinetics compared with several competitors.
See our latest analysis for HBM Holdings.
At a share price of HK$12.15, HBM Holdings has seen the 30 day share price return fall 13.21%, even as the 1 year total shareholder return is 37.91% and the 3 year total shareholder return is very large. This...